Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A Better Way to Treat ACE Inhibitor Angioedema in the ED

15.05.2014

Investigators at the University of Cincinnati have found a safe and effective treatment for life-threatening angioedema attacks in the emergency department.

In angioedema, patients experience a rapid swelling of the skin and subcutaneous tissues—which, in some cases, can lead to airway obstruction and suffocation. Physicians usually treat angioedema like an allergic reaction with corticosteroids and antihistamines.


Joseph Moellman, MD, in the emergency department at University Hospital performing a skin test for penicillin allergy

But that therapy doesn’t always work for another version of the condition, thought to be caused by taking a class of drugs known as ACE inhibitors.

"ACE inhibitors are a common treatment in patients with congestive heart failure and hypertension,” says Joseph Moellman, MD, associate professor of emergency medicine. "It is also the most common etiology of patients presenting to the emergency department with angioedema.”

... more about:
»ACE »Bernstein »Medicine »drugs »hypertension »therapy

Moellman says there’s currently no treatment for ACE inhibitor induced (ACEI) angioedema, as the physiology of the condition is different—caused by the levels of the blood vessel-dilating peptide bradykinin in the body.

In a triple blind, placebo-controlled phase-2 trial, Moellman worked with professor of medicine and angioedema expert Jonathan Bernstein, MD, and fellow researchers at the UC Medical Center Emergency Department to study the drug Ecallantide in the treatment of ACEI angioedema that failed to respond to the conventional therapy of corticosteroids and antihistamines.

They wanted to see if Ecallantide, which has already safely treated acute attacks of hereditary angioedema, could help patients with ACEI angioedema—specifically, if it could make them eligible for discharge within four hours of treatment.

After enrolling 50 patients in the study, they found that patients treated with Ecallantide were more likely to meet discharge sooner than those receiving antihistamines and steroids—31 percent of Ecallantide patients were eligible for discharge within four hours, as compared with 21 percent of patients receiving placebos. Additionally, patients experienced few side effects from the medication.

Moellman says the data supports launching a phase-3 trial, which will enroll more patients to confirm the initial results.  He is presenting the results at the annual meeting of the Society for Academic Emergency Medicine, held May 14-17 in Dallas.

Co-authors of the study include Christopher Lindsell, PhD, Kimberly Hart and Sean Collins, MD. The study was funded by Dyax, manufacturer of Ecallantide, or Kalibtor. Bernstein is a consultant and speaker for Dyax.

Kathryn Cosse | Eurek Alert!

Further reports about: ACE Bernstein Medicine drugs hypertension therapy

More articles from Health and Medicine:

nachricht Punctuating messages encoded in human genome with transposable elements
04.08.2015 | Aelan Cell Technologies

nachricht Real-time imaging of lung lesions during surgery helps localize tumors and improve precision
30.07.2015 | American Association for Thoracic Surgery

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Greenhouse gases' millennia-long ocean legacy

Continuing current carbon dioxide (CO2) emission trends throughout this century and beyond would leave a legacy of heat and acidity in the deep ocean. These...

Im Focus: Glaciers melt faster than ever

Glacier decline in the first decade of the 21st century has reached a historical record, since the onset of direct observations. Glacier melt is a global phenomenon and will continue even without further climate change. This is shown in the latest study by the World Glacier Monitoring Service under the lead of the University of Zurich, Switzerland.

The World Glacier Monitoring Service, domiciled at the University of Zurich, has compiled worldwide data on glacier changes for more than 120 years. Together...

Im Focus: Quantum Matter Stuck in Unrest

Using ultracold atoms trapped in light crystals, scientists from the MPQ, LMU, and the Weizmann Institute observe a novel state of matter that never thermalizes.

What happens if one mixes cold and hot water? After some initial dynamics, one is left with lukewarm water—the system has thermalized to a new thermal...

Im Focus: On the crest of the wave: Electronics on a time scale shorter than a cycle of light

Physicists from Regensburg and Marburg, Germany have succeeded in taking a slow-motion movie of speeding electrons in a solid driven by a strong light wave. In the process, they have unraveled a novel quantum phenomenon, which will be reported in the forthcoming edition of Nature.

The advent of ever faster electronics featuring clock rates up to the multiple-gigahertz range has revolutionized our day-to-day life. Researchers and...

Im Focus: Superfast fluorescence sets new speed record

Plasmonic device has speed and efficiency to serve optical computers

Researchers have developed an ultrafast light-emitting device that can flip on and off 90 billion times a second and could form the basis of optical computing.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Success 4.0 – Is Your Company Fit for the Future? New Series of Events for Executives

04.08.2015 | Event News

3rd Euro Bio-inspired - International Conference and Exhibition on Bio-inspired Materials

23.07.2015 | Event News

Clash of Realities – International Conference on the Art, Technology and Theory of Digital Games

10.07.2015 | Event News

 
Latest News

New STN Breaks Ground with Markush Structure Search and Enhanced Content for IP Exploration

05.08.2015 | Business and Finance

When new parents become unhappy, brothers and sisters become less likely

05.08.2015 | Social Sciences

Small tilt in magnets makes them viable memory chips

04.08.2015 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>